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Abstract
Background: Men who have sex with men (MSM) with bacterial STDs are at elevated risk for 
HIV. We evaluated the integration of pre-exposure prophylaxis (PrEP) referrals into STD partner 
services (PS) for MSM.
Setting: King County, Washington
Methods: Disease Intervention Specialists (DIS) in King County attempt to provide PS to all 
MSM with early syphilis and, as resources allow, MSM with gonorrhea or chlamydia. Our health 
department defines MSM with any of the following as at high HIV risk: early syphilis, rectal 
gonorrhea, methamphetamine/poppers use, sex work, or an HIV-unsuppressed partner. DIS offer 
high-risk MSM referral to our STD Clinic for PrEP and other MSM referral to community 
providers. In 2017, we interviewed a random sample of MSM offered referrals in 2016 to assess 
PrEP initiation following PS.
Results: From 8/2014-8/2017, 7546 cases of bacterial STDs were reported among HIV-negative 
MSM. DIS provided PS to 3739 MSM, of whom 2055 (55%) were at high risk. DIS assessed PrEP 
use in 1840 (90%) of these men, 895 (49%) of whom reported already using PrEP. DIS offered 
referrals to 693 (73%) of 945 MSM not on PrEP; 372 (54%) accepted. Among 132 interviewed for 
the random sample, men who accepted referrals at initial interview were more likely to report 
using PrEP at follow-up (32/68=47%) than those who did not (12/64=19%) [p=0.0006]. 10.4% of 
all interviewed MSM initiated PrEP following PS-based referral.
Conclusions: Integrating PrEP referrals into STD PS is an effective population-based strategy to 
link MSM at high HIV risk to PrEP.
Requests for reprints should be addressed to corresponding author. Corresponding author: David A. Katz, PhD, MPH, University of 
Washington, 325 Ninth Avenue, Box 359931, Seattle, WA 98104, Telephone: 206-744-5877, dkatz7@uw.edu. 
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INTRODUCTION
HIV pre-exposure prophylaxis is effective at preventing new HIV infections among men 
who have sex with men (MSM)1–3, and clinical and public health guidelines recommend 
PrEP for populations at substantial risk for HIV infection4–7. Since its introduction in 2012, 
PrEP use has increased rapidly among MSM in the U.S., but many MSM with indications 
for PrEP have not been reached and uptake has varied widely by region, age, and race/
ethnicity8–10. Identifying acceptable, effective, and equitable approaches for promoting PrEP 
use among MSM is critical to the successful implementation of this effective intervention.
Diagnosis with bacterial sexually transmitted diseases (STDs) has long been associated with 
risk for HIV diagnosis and acquisition11–13, and recent studies have identified early syphilis 
and rectal infections, in particular, as associated with future HIV acquisition among 
MSM14–19. These infections are legally reportable to health departments throughout the 
U.S., nearly all health departments routinely provide partner services (PS) to people 
diagnosed with early syphilis, and some selectively provide these services to people with 
gonorrhea or chlamydia20. As a result, public health STD PS may represent a population-
based opportunity to link people at high risk of acquiring HIV to PrEP and, insofar as black 
and Latino MSM have higher rates of STD diagnosis than other MSM19,21–23, to reduce 
racial/ethnic inequities in PrEP use.
As part of a broader effort to leverage STD PS for HIV prevention in Washington State, 
Public Health–Seattle & King County (PHSKC) began routinely asking about current PrEP 
use and offering referrals to PrEP care for HIV-negative MSM not currently on PrEP as part 
of PS interviews in October 2014. Here, we describe an evaluation of the uptake and 
effectiveness of PS-based PrEP referrals and the use of PS data to monitor PrEP use among 
MSM with STDs.
METHODS
STD case reporting
Medical providers in Washington State are legally required to complete a case report for 
each person they diagnose with syphilis, gonorrhea, or chlamydia. This form includes 
gender of sex partners and anatomical site of gonococcal and chlamydial infection, allowing 
health departments to identify MSM. Laboratories are also required to report these 
infections, and public health staff follow-up on laboratory-reported cases to ensure case 
reports are complete.
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Partner services intervention
In October 2014, PHSKC began offering PrEP at its STD Clinic. In preparation, disease 
intervention specialists (DIS) began assessing PrEP use among and offering referrals for 
PrEP to select clients in August 2014. (DIS are public health staff who conduct outreach 
investigations, including PS.) We initially limited assessment and referrals to MSM with 
early syphilis, the population with the highest prevalence of undiagnosed HIV infection at 
the time of STD diagnosis24. Informed by analyses examining correlates of HIV incidence 
among local MSM16,25, we expanded PrEP assessment to include all MSM receiving PS and 
referrals to include MSM diagnosed with rectal gonorrhea in May 2015. Then, following the 
introduction of statewide PrEP implementation guidelines6, we expanded referrals to all 
MSM receiving PS in January 2016.
PHSKC uses the Washington State PrEP Implementation Guidelines to define priority 
populations for PrEP referral. The guidelines define two categories of HIV risk, a high risk 
group for whom providers should initiate PrEP and an intermediate risk group with whom 
providers should discuss PrEP initiation. MSM are considered at high risk if they meet any 
of the following criteria: diagnosis of early syphilis or rectal gonorrhea; methamphetamine 
or poppers use or sex work in the prior year; or an ongoing sexual partnership with an HIV-
positive person whose viral load is not suppressed or who is not taking or recently started 
antiretroviral therapy6,16. MSM are considered at intermediate risk if they meet any of the 
following criteria: condomless anal sex outside of a long-term mutually monogamous 
relationship an HIV-negative partner; diagnosis of chlamydial infection or urethral or 
pharyngeal gonorrhea; an ongoing sexual partnership with an HIV-positive partner who is on 
antiretroviral therapy and is virologically suppressed; injection drug use; seeking a 
prescription for PrEP; or completing a course of post-exposure prophylaxis. DIS assess risk 
status based on STD diagnosis from the case report and the case’s self-reported behaviors. 
DIS offer referrals to the PHSKC STD Clinic to high risk MSM and to community PrEP 
providers to high risk MSM who refuse STD clinic referrals and intermediate risk MSM.
Population and data
HIV-negative MSM reported to PHSKC with early syphilis, gonorrhea, or chlamydia from 
August 2014-August 2017 were included in this analysis. We defined men as MSM if they 
reported sex with men in the prior year during PS interviews, their provider indicated male 
sex partners on the case report, or they were diagnosed with rectal gonorrhea or rectal 
chlamydia. The Washington State Department of Health routinely matches local STD 
reporting data with the state’s Enhanced HIV/AIDS Reporting System (eHARS)24. We 
excluded men diagnosed with HIV prior to or at the time of STD diagnosis based on eHARS 
HIV diagnosis dates or self-report during PS interview.
Initiation of PrEP care and PrEP utilization
We conducted two assessments of PrEP care initiation and use following referrals. First, for 
the entire evaluation period, we linked records from people accepting PrEP referrals to the 
STD clinic PrEP program database to determine which high risk men attended at least 1 
PrEP-related clinic visit after their PS interview. If MSM accepted multiple referrals to the 
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STD clinic before attending a clinic visit, only the referral immediately prior to the clinic 
visit was considered to have resulted in a PrEP visit.
Second, we conducted an analysis of MSM PS recipients in 2016, the first year during which 
we offered all HIV-negative MSM referrals to PrEP, to estimate the proportion of MSM who 
initiated PrEP following PS. We conducted follow-up interviews with a random sample of 
50% of MSM who were offered PrEP referrals during their PS interviews in 2016. To create 
the sample, we stratified these cases into four groups by whether they accepted a PrEP 
referral and risk category (high vs. intermediate). We used the latest interview in 2016 if an 
individual was interviewed more than once. The sample included 189 cases distributed 
equally across the four strata. A single DIS attempted to re-interview sampled cases from 
April-September 2017 and asked respondents whether they had used PrEP at any time 
following initial PS interview. Among respondents not currently using PrEP, the DIS 
assessed respondents’ HIV risk, offered additional PrEP referrals, and asked about barriers 
to PrEP initiation.
Statistical analysis
We calculated the proportions of cases receiving PS who were asked about PrEP, already 
taking PrEP, offered PrEP referrals by DIS, accepted referrals, and (among those accepting 
referrals to the STD clinic) attended at least 1 visit for PrEP care. We compared outcomes 
across strata using chi-square tests. We assessed correlates of PrEP use (among those whose 
PrEP use was assessed) and acceptance of a PrEP referral (among those offered referrals) at 
initial interview using chi-square tests for bivariable analyses and Poisson regression with 
robust variance for multivariable analyses. We used STD cases as the unit of analysis 
because our intervention was delivered at the case level.
We examined temporal trends in PrEP use overall and by HIV risk using the Mantel-
Haenszel chi-square test for trend. Because PrEP users test frequently for STDs, leading to 
increased ascertainment of asymptomatic infections, we also evaluated trends among MSM 
with symptomatic infections (defined as urethral gonorrhea and primary/secondary syphilis) 
as a measure less likely to be affected by ascertainment bias. To address the potential for 
MSM receiving PS more than once per year to bias estimates of PrEP use, we conducted a 
sensitivity analysis using only one case per year for each unique person. In this analysis, 
MSM who had PrEP use assessed during more than one PS interview in a given year had a 
single interview randomly selected for inclusion; however, MSM could contribute data in 
multiple years.
Among men interviewed for the random sample, we assessed correlates of completing a 
follow-up interview and compared the proportion reporting current PrEP use among those 
who accepted vs. declined referrals overall and within risk strata using chi-square tests. We 
calculated the number needed to interview (NNTI) for one client to initiate PrEP in two 
ways: (1) assuming that all PrEP initiations following acceptance of a PS-based referral 
could be attributed to the referral and (2) assuming the rate of PrEP initiation observed in 
men who refused referrals represented a background rate that would have occurred without 
our intervention. (For details and full equations, see Supplemental Digital Content 1). 
Finally, we described progress towards PrEP initiation and barriers to PrEP experienced by 
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people who did not initiate PrEP following a referral as well as acceptance of new referrals 
at follow-up.
Analyses were conducted using SAS 9.4 (SAS Institutes, Cary, NC) and Stata version 15 
(College Station, TX). These activities were conducted as part of public health program 
evaluation and therefore not considered human subjects research.
RESULTS
Population
From August 1, 2014, through August 30, 2017, 7546 cases of early syphilis, gonorrhea, or 
chlamydia were reported among 5036 unique HIV-negative MSM in King County, 
Washington, of whom 3739 (50%) cases were interviewed for PS, including 71% of MSM 
with early syphilis or rectal gonorrhea and 41% of MSM with other reportable STDs (Table 
1). Cases who were under age 35, Hispanic/Latino, and diagnosed with gonorrhea or early 
syphilis were more likely to receive PS (p<0.01 for all).
Of the 3739 PS recipients, most were non-Latino White (61%) or Latino (19%). The median 
age was 30 [interquartile range (IQR)=25-38], and 23% reported poppers use, 4% 
methamphetamine use, and 38% ≥10 male sex partners in the prior year. Overall, 2055 
(55%) were at high HIV risk and eligible to receive PrEP at the STD clinic, 1374 (67%) of 
whom were diagnosed with early syphilis or rectal gonorrhea and 538 (33%) had other 
infections and at least one behavior defining them as at high risk per local guidelines (Table 
1). Twenty-four percent of cases diagnosed with chlamydia or urethral or pharyngeal 
gonorrhea were considered high risk.
PrEP use prior to STD PS
Of the 3238 PS recipients who were asked about current PrEP use (87% of total recipients), 
1330 (41%) reported being on PrEP. MSM at high risk were more likely to report being on 
PrEP than men at intermediate risk (49% vs. 31%, p<0.0001). In multivariable analyses, 
being on PrEP was associated with being non-Latino white, age 30-44, using poppers, 
having ≥10 or an unknown number of male sex partners in the prior year, more recent year 
of diagnosis, and diagnosis with early syphilis, rectal infections, or pharyngeal chlamydia 
(Table 2).
Trends in PrEP use
The proportion of HIV-negative MSM who were on PrEP at the time of PS interview 
increased from 19% in 2014 to 51% in 2017 among MSM with all STDs and from 14% to 
42% among those with symptomatic STDs (p<0.001 for both; Fig. 1A). Similar trends were 
observed when stratifying by HIV risk (Fig. 1B) and by age and race/ethnicity (data not 
shown) with men at high risk, ages 35-44, and non-Latino white consistently reporting the 
highest use. In a sensitivity analysis accounting for men receiving PS more than once in a 
year, we found nearly identical estimates of overall PrEP use over time, increasing from 
19% in 2014 to 50% in 2017 (p<0.001).
Katz et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2020 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PrEP referral through STD PS
During the evaluation period, DIS offered PrEP referral to 693 (71%) of the 945 high risk 
MSM PS recipients who were not already on PrEP (Table 1). Of those offered, 372 (54%) 
accepted a referral, 253 (68%) to the STD clinic and 119 (32%) to community providers. Of 
those referred to the STD clinic, 145 (57%) had attended an initial PrEP evaluation 
appointment at the clinic as of November 9, 2017, 125 (49%) within 3 months of PS 
interview. Overall, 7% of HIV-negative MSM receiving PS and 21% of those offered a 
referral to the STD clinic for PrEP attended an evaluation appointment at the STD clinic 
(Fig. 2A). Referral outcomes for intermediate risk MSM and stratified by HIV risk criteria 
are presented in Table 1.
Random sample: PrEP uptake
In 2016, 377 HIV-negative/unknown MSM received STD PS, reported not being on PrEP at 
the time of the interview, and were offered a referral for PrEP (Table 3). Of these, 189 (50%) 
were randomly sampled for follow-up interviews conducted April-September 2017, of 
whom 132 (70%) were interviewed a median of 315.5 days (IQR=254-393) following their 
initial PS interview, 56 (29%) could not be contacted, and 1 (1%) refused to be interviewed. 
Response rates did not differ significantly by age, race/ethnicity, or strata defined by referral 
acceptance and risk status (p>0.2 for all).
PrEP uptake following initial PS interview and acceptance of new referrals among those 
who reported not being on PrEP are described in Table 3. Overall, 44 (33%) of the 132 with 
a follow-up interview reported being on PrEP at follow-up and 4 (2%) had initiated PrEP but 
discontinued it. Of current PrEP users, 70% were prescribed PrEP by community providers, 
and 98% reported taking >4 doses in the prior 7 days. Men who accepted referrals at initial 
interview were significantly more likely to be using PrEP at follow-up (32/68=47%) than 
those who did not (12/64=19%) [relative risk (RR) = 2.51, 95% confidence interval (CI): 
1.42-4.43; p=0.0006]. This effect was greater among high risk men (3.34, 1.56-7.15; 
p=0.0002) than intermediate risk men (1.62, 0.66-3.95; p=0.28).
Reweighting responses by the proportion of PS recipients in each strata of the random 
sample, 40% of all men offered referrals and 56% of those who accepted referrals reported 
having initiated PrEP following PS. Applying estimates from the random sample to overall 
PS and PrEP referral outcomes from 2016 suggests that 32% of high risk and 9% of 
intermediate risk MSM who received PS and were not already using PrEP initiated PrEP 
following their interview (Fig. 2B) and that 10.4% of all interviewed HIV-negative MSM 
(including those previously on PrEP) initiated PrEP following a referral provided via PS. 
This corresponds to a NNTI for one client to initiate PrEP following PS referral of 9.6. 
Assuming the rate of PrEP initiation observed in men who refused referrals represents a 
background rate that would have occurred in the absence of our intervention, 6.5% of 
interviewed MSM initiated PrEP as a consequence of PS-based referral, and the NNTI was 
15.
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Random sample: Barriers to PrEP use and acceptance of new referrals
Of the 33 randomly sampled men who accepted a referral at the initial interview but did not 
initiate PrEP, 27 remembered receiving a referral, of whom 8 (30%) decided they were not 
interested in PrEP, 15 (56%) were interested but did not contact a provider, 2 (7%) scheduled 
an appointment with a provider but did not attend, 1 (4%) reported having an upcoming 
appointment, and 1 (4%) had an appointment but decided against initiating PrEP. Among the 
33 referred, the most commonly reported barriers to PrEP were not thinking they were at 
risk (45%) and the frequency of provider visits for follow-up (42%) [complete table of 
barriers available as Supplementary Digital Content 2].
Of the 88 men who reported not being on PrEP at follow-up, 39 (44%) were interested in 
starting PrEP, 30 (77%) of whom accepted a referral to a PrEP provider or indicated they 
would seek PrEP from their own medical provider (Table 3). Of men interested in starting 
PrEP, 27 (69%) were identified as being at high risk based on their follow-up interview, 
including 13 of 24 who had been classified as intermediate risk at initial interview.
DISCUSSION
We found that routinely offering referrals to PrEP providers as part of STD PS for MSM was 
both feasible and effective at increasing PrEP uptake, particularly among men at highest risk 
for HIV. Approximately half of MSM PS recipients accepted referrals when offered, 
accepting a referral was associated with a 2.5-fold increase in PrEP use following PS, and in 
our experience, approximately 1 in 3 MSM who accepted referrals through PS initiated 
PrEP. While we regard this level of uptake as a success, we observed significant attrition 
along the continuum from offering referrals to PrEP initiation, highlighting the need to 
improve intervention delivery throughout the process. Additionally, we found that following 
up with men after their initial PS interview provided an opportunity to address barriers to 
PrEP use and offer additional referrals.
Our results highlight how PrEP promotion can be successfully integrated into STD PS, one 
of several opportunities to broaden the focus of PS to address related public health 
objectives26. We previously reported that STD PS can be used to increase HIV testing 
among MSM24 and identify people with HIV who are inadequately engaged in care27. Here, 
we found that approximately one of every 10 MSM receiving STD PS can be successfully 
referred to initiate PrEP. These findings should prompt health departments to expand the 
objectives of STD PS and consider using HIV-specific resources to fund these more broadly 
conceived programs.
Our ability to successfully integrate PrEP referrals into PS was facilitated by several factors: 
the large number of PrEP providers in our area, our ability to identify MSM before initiating 
PS using case report data, DIS coordination of our public health PrEP program, and the 
relative paucity of financial barriers to PrEP resulting from Washington State’s expansion of 
Medicaid and statewide PrEP drug assistance program28. These factors likely increased the 
effectiveness of PrEP referrals in our setting and may impact other jurisdictions’ ability to 
reproduce our program. However, the high underlying rate of PrEP use among MSM limited 
the number of men eligible for referral. Integrating PrEP promotion into STD PS may have 
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even more potential for benefit in settings with less PrEP use, particularly if paired with 
PrEP clinical care or navigation services.
Our findings also demonstrate how assessing PrEP use during PS interviews can help health 
departments monitor PrEP use in a population of MSM at high risk for HIV. Consistent with 
other local analyses29,30, we found that PrEP use has dramatically increased among MSM in 
King County since 2014. In 2017, just over half of PS recipients were on PrEP. Of note, 42% 
of MSM with symptomatic STDs–infections unlikely to have been detected as a result of 
PrEP-related screening–were on PrEP, indicating that the high level of PrEP use we 
observed was not simply a consequence of PrEP-related STD testing. This final estimate is 
only slightly higher than other recent local estimates from behavioral and sentinel 
surveillance of PrEP use among MSM at high and intermediate risk, which range from 35–
39%30. Despite this success, we identified significant and sustained racial/ethnic inequities 
in PrEP use. Of particular importance, as in many other settings8–10,31–33, black and Latino 
MSM, populations that experience higher HIV incidence than white MSM in the U.S.34 and 
locally30, were less likely to be using PrEP. This uneven uptake of PrEP has the potential to 
further increase inequities in HIV incidence. Integrating PrEP promotion into STD PS has 
particular potential to help address these inequities because it is population-based and 
because black and Latino MSM are also disproportionately affected by STDs19,21–23.
This program evaluation has some limitations. First, we relied on self-report when assessing 
PrEP use. Second, we were unable to assess the success of referrals for all MSM receiving 
PS and relied on conducting interviews with a random sample of 2016 cases to assess uptake 
and effectiveness of referrals. Third, although we found a strong association between 
referrals and PrEP initiation, this was an observational study, and we cannot directly 
attribute PrEP initiation to our intervention. Finally, not all MSM diagnosed with STDs may 
have been identified as MSM and prioritized for PS, PS recipients differed from men who 
refuse PS or could not be located, assessment of PrEP use improved over time (data not 
shown) and differed by risk criteria, and some men were diagnosed with multiple STIs and 
received PS more than once over the evaluation period, potentially biasing our estimates of 
PrEP use.
In conclusion, STD PS represent an opportunity to promote PrEP to a large and diverse 
population of MSM at high risk for HIV and provide a population-based estimate of PrEP 
use in this population. PrEP promotion should be considered as an outcome of syphilis PS, 
and health departments should consider expanding PS programs to MSM with STDs other 
than syphilis with HIV prevention as an explicit goal.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Temporal trends in reported PrEP use among HIV-negative MSM receiving STD 
partner services, August 2014-August 2017.
Presented overall and among symptomatic STDs only (Panel A) and by HIV risk strata 
(Panel B). Limited to men whose PrEP use was assessed as part of the partner services 
interview. Symptomatic STDs were defined as urethral gonorrhea and primary or secondary 
syphilis. GC = gonorrhea.
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Figure 2. STD partner services (PS) provision, PrEP use, and acceptance of PrEP referrals 
among HIV-negative MSM diagnosed with bacterial STDs in King County, Washington.
Presented among MSM at the highest risk for HIV acquisition, August 2014-August 2017 
(Panel A) and among all MSM diagnosed in 2016 (Panel B). For August 2014-August 2017 
(A), assessment of PrEP uptake was limited to attendance at a PrEP evaluation visit at the 
Public Health – Seattle & King County STD Clinic. For 2016 (B), PrEP initiation and 
current use was assessed during follow-up interviews of a random sample of who were 
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offered PrEP referrals during their PS interview in 2016 (includes PrEP initiation and use 
within and outside the STD Clinic).
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